

Benign Prostatic Hyperplasia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/B00FA164F97EEN.html>

Date: October 2022

Pages: 74

Price: US\$ 2,000.00 (Single User License)

ID: B00FA164F97EEN

Abstracts

Benign Prostatic Hyperplasia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Benign Prostatic Hyperplasia - Drugs In Development, 2022, provides an overview of the Benign Prostatic Hyperplasia (Male Health) pipeline landscape.

Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, difficulty starting a urine stream. Treatment options for BPH include surgery and medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Benign Prostatic Hyperplasia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Benign Prostatic Hyperplasia (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 4, 3, 1, 6, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Benign Prostatic Hyperplasia (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia (Male Health).

The pipeline guide reviews pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Benign Prostatic

Hyperplasia (Male Health) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Benign Prostatic Hyperplasia (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Benign Prostatic Hyperplasia (Male Health).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia (Male Health) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Benign Prostatic Hyperplasia - Overview
- Benign Prostatic Hyperplasia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Benign Prostatic Hyperplasia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development
- AiViva BioPharma Inc
- Aphios Corp
- Aquestive Therapeutics Inc
- ASKA Pharmaceutical Holdings Co Ltd
- BCWorld Pharm Co Ltd
- Boryung Pharmaceutical Co Ltd
- Chengdu Dikang Pharmaceuticals Co Ltd
- Chong Kun Dang Pharmaceutical Corporation
- Curadis GmbH
- DongKoo Bio & Pharma Co Ltd
- Dongkook Pharmaceutical Co Ltd
- GemVax & KAEL Co Ltd
- Genu Pharma Co Ltd
- Geropharm
- Hanmi Pharmaceuticals Co Ltd
- Jiangsu Kangyuan Pharmaceutical Co Ltd
- Kwang Dong Pharmaceutical Co Ltd
- Nymox Pharmaceutical Corp
- Sentan Pharma Inc
- ValiRx Plc
- Veru Inc
- XuanZhu Biological Technology Co Ltd

Benign Prostatic Hyperplasia - Drug Profiles

(dutasteride + tadalafil) - Drug Profile

Product Description

Mechanism Of Action

(dutasteride + tamsulosin hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

(finasteride + tadalafil) - Drug Profile

Product Description

Mechanism Of Action

(mirabegron + tamsulosin hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

AIV-007 - Drug Profile

Product Description

Mechanism Of Action

AKP-009 - Drug Profile

Product Description

Mechanism Of Action

BCWPE-004 - Drug Profile

Product Description

Mechanism Of Action

BR-9006 - Drug Profile

Product Description

Mechanism Of Action

CKD-843 - Drug Profile

Product Description

Mechanism Of Action

CR-1447 - Drug Profile

Product Description

Mechanism Of Action

DDCI-01 - Drug Profile

Product Description

Mechanism Of Action

Drug for Benign Prostatic Hyperplasia and Overactive Bladder - Drug Profile

Product Description

Mechanism Of Action

fadanafil - Drug Profile

Product Description

Mechanism Of Action

fexapotide triflutate - Drug Profile

Product Description

Mechanism Of Action

GP-20051 - Drug Profile

Product Description

Mechanism Of Action

KD-304 - Drug Profile

Product Description

Mechanism Of Action

KKM-1202 - Drug Profile

Product Description

Mechanism Of Action

Quinolixin - Drug Profile

Product Description

Mechanism Of Action

S-0131632 - Drug Profile

Product Description

Mechanism Of Action

SP-0051 - Drug Profile

Product Description

Mechanism Of Action

Sperol - Drug Profile

Product Description

Mechanism Of Action

tadalafil - Drug Profile

Product Description

Mechanism Of Action

tamsulosin SR - Drug Profile

Product Description

Mechanism Of Action

tertomotide - Drug Profile

Product Description

Mechanism Of Action

VAL-301 - Drug Profile

Product Description

Mechanism Of Action

Benign Prostatic Hyperplasia - Dormant Projects

Benign Prostatic Hyperplasia - Discontinued Products

Benign Prostatic Hyperplasia - Product Development Milestones

Featured News & Press Releases

Dec 13, 2021: Veru announces FDA approval of ENTADFI, a new treatment for benign prostatic hyperplasia

Feb 23, 2021: Veru submits new drug application for proprietary TADFIN for BPH

Jul 10, 2020: Ministry OKs Dongkook's P3 trial into benign prostatic hyperplasia treatment

Oct 23, 2019: GV1001, shows efficacy as a treatment for Benign Prostatic Hyperplasia

Jun 26, 2019: Veru announces successful completion of pre-NDA meeting with FDA for tadalafil (tadalafil 5mg and finasteride 5mg) combination for the treatment of benign prostatic hyperplasia

Apr 05, 2019: Gemvax & Kael's wins nod for P3 trial of benign prostatic hyperplasia treatment

Jan 31, 2019: ValiRx received Russian Federation & Chinese patent grant allowances for therapeutic compound, VAL301

Jan 14, 2019: Veru Plans to Submit NDA in 2019

Dec 03, 2018: Veru announces first patient dosed in bioequivalence clinical trial for combination Tadalafil - Finasteride tablet for benign prostatic hyperplasia

Apr 16, 2018: GemVax & KAEL Announces Positive Phase 2 Data on GV1001 for Prostate Hyperplasia

Dec 14, 2016: CFDA Granted Approval for Phase I/II/III Clinical Trials of Sihuan Pharmaceutical's Internally Developed Innovative Patented New Drug - Fadanafil

Jul 26, 2010: Aphios Awarded United States Patent For Compositions And Methods For Inhibiting 5-Alpha Reductase

Mar 02, 2010: Impax Receives Final FDA Approval For Generic FLOMAX 0.4mg Capsules

Oct 07, 2009: Impax Laboratories Settles Pending Litigation for FLOMAX

Oct 05, 2009: Impax Laboratories Receives Tentative FDA Approval for Generic FLOMAX 0.4mg Capsules

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Benign Prostatic Hyperplasia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Benign Prostatic Hyperplasia - Dormant Projects, 2022

Benign Prostatic Hyperplasia - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Benign Prostatic Hyperplasia, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Benign Prostatic Hyperplasia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/B00FA164F97EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B00FA164F97EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

